Solvonis Therapeutics PLC (SVNS)

London
Currency in GBP
0.19
-0.01(-5.26%)
Closed
SVNS Scorecard
Full Analysis
Quickly burning through cash
Fair Value
Day's Range
0.180.19
52 wk Range
0.101.41
Key Statistics
Edit
Bid/Ask
0.17 / 0.20
Prev. Close
0.19
Open
0.18
Day's Range
0.18-0.19
52 wk Range
0.1-1.41
Volume
8.4M
Average Vol. (3m)
24.62M
1-Year Change
-72.86%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SVNS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Solvonis Therapeutics PLC Company Profile

Solvonis Therapeutics plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for combining various polymers with fiberglass, carbon fiber, mineral, natural fillers, and mixed polymer waste; GRAFTALEN, a line of reactive solid super-concentrates for polyolefin rheology modification, e-modulus enhancers, PET/PBT chain extenders, and AOX masterbatch; and GRAFTAPOR, a line of porous polymer-carriers for use in liquid chemicals. It also provides GRAFTAMID, a line of high-temperature elastomers based on nanostructured polyolefin-polyamide alloys for high-tech hardening modifiers in polyamide compounds, as well as use as an independent compound in hot melt adhesives; and GRAFTAKIT, a reactive liquid or solid super-concentrates on polymeric porous media for carrying out reaction extrusion and modification of compounds. In addition, the company offers GRAFTALLOY, a line of polymer-polymer nano-alloys to increase abrasion and temperature resistance, and impact strength, as well as reduce friction coefficient; GRAFTASYNT, a line of synthetic products comprising halogen-free flame retardants; and GRAFTAMER, a thermo-reversible crosslinking, self-hardening, and self-healing smart polymer with shape memory, etc. Solvonis Therapeutics plc has a collaboration agreement with Awakn Life Sciences Corp. to develop novel aminoindane new chemical entity series program (Aminoindane NCEs) for the treatment of trauma-related mental health disorders. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Compare SVNS to Peers and Sector

Metrics to compare
SVNS
Peers
Sector
Relationship
P/E Ratio
−1.8x−0.3x−0.1x
PEG Ratio
−0.09−0.140.00
Price / Book
2.6x1.3x1.6x
Price / LTM Sales
12.6x1.1x1.2x
Upside (Analyst Target)
-63.9%29.4%
Fair Value Upside
Unlock25.8%2.5%Unlock

Earnings

Latest Release
Apr 27, 2023
EPS / Forecast
-0.02 / --
Revenue / Forecast
211.00K / --
EPS Revisions
Last 90 days

People Also Watch

5.05
POLB
-0.98%
7.34
KMK
+4.86%
1.48
POLX
0.00%
0.484
KEFI
+1.47%

FAQ

What Is the Solvonis Therapeutics (SVNS) Stock Price Today?

The Solvonis Therapeutics stock price today is 0.19

What Stock Exchange Does Solvonis Therapeutics Trade On?

Solvonis Therapeutics is listed and trades on the London stock exchange.

What Is the Stock Symbol for Solvonis Therapeutics?

The stock symbol for Solvonis Therapeutics is "SVNS."

What Is the Solvonis Therapeutics Market Cap?

As of today, Solvonis Therapeutics market cap is 4.25M.

What is Solvonis Therapeutics Earnings Per Share?

The Solvonis Therapeutics EPS is -0.023.

From a Technical Analysis Perspective, Is SVNS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.